Literature DB >> 12738950

C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma.

Paul C Edwards1, Tawfigul Bhuiya, Robert D Kelsch.   

Abstract

OBJECTIVE: Differentiating between adenoid cystic carcinomas (ACCs), polymorphous low-grade adenocarcinomas (PLGAs), and the monomorphic adenomas (including canalicular adenomas, trabecular adenomas, and basal cell adenomas) can present a diagnostic challenge, especially when examining tissue obtained from small incisional or fragmented biopsies. Recent studies have revealed that overexpression of the tyrosine kinase receptor protein c-kit occurs in a narrow subset of malignant neoplasms, including gastrointestinal stromal tumors, myeloid leukemias, seminomas, and ACCs. C-kit reportedly is not expressed in PLGAs. We compared the expression of the c-kit antigen in the malignant salivary gland neoplasms ACC and PLGA with its expression in salivary gland monomorphic adenoma (including canalicular adenoma and basal cell adenoma). STUDY
DESIGN: Formalin-fixed paraffin-embedded sections of 49 salivary gland neoplasms (17 monomorphic adenomas, 17 PLGAs, and 15 ACCs) accessioned between 1989 and 2002 were retrieved from the files of the Department of Pathology, Long Island Jewish Medical Center, and were stained with an anti-c-kit polyclonal antibody.
RESULTS: C-kit reactivity was uniformly positive in the cytoplasm of luminal neoplastic cells in ACCs (15/15, 100%). Positive reactivity was also identified in the majority of PLGAs (16/17, 94%), with at least 25% of the tumor cells being positive. Similar reactivity was seen in monomorphic adenomas (16/17, 94%).
CONCLUSIONS: In contrast to previous reports, we find that c-kit expression was not restricted to ACC but was expressed in all 3 tumor types evaluated (ACC, PLGA, and monomorphic adenoma). Therefore, c-kit does not appear to be a useful marker for distinguishing between either ACC and PLGA in equivocal cases, or in benign and malignant salivary gland neoplasms.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738950     DOI: 10.1067/moe.2003.31

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  38 in total

1.  SOX10 and GATA3 in Adenoid Cystic Carcinoma and Polymorphous Adenocarcinoma.

Authors:  Brian D Adkins; Ariana Geromes; Lily Y Zhang; Rebecca Chernock; Katherine Kimmelshue; James Lewis; Kim Ely
Journal:  Head Neck Pathol       Date:  2019-06-20

2.  Expression of miRNAs in adenoid cystic carcinomas of the breast and salivary glands.

Authors:  Orsolya Kiss; Anna-Mária Tőkés; Semir Vranic; Zoran Gatalica; László Vass; Nóra Udvarhelyi; A Marcell Szász; Janina Kulka
Journal:  Virchows Arch       Date:  2015-08-21       Impact factor: 4.064

Review 3.  Canalicular adenoma: a clinicopathologic and immunohistochemical analysis of 67 cases with a review of the literature.

Authors:  Lester D R Thompson; Justin L Bauer; Simion Chiosea; Jonathan B McHugh; Raja R Seethala; Markku Miettinen; Susan Müller
Journal:  Head Neck Pathol       Date:  2014-08-21

4.  Morphological heterogeneity of oral salivary gland carcinomas: a clinicopathologic study of 41 cases with long term follow-up emphasizing the overlapping spectrum of adenoid cystic carcinoma and polymorphous low-grade adenocarcinoma.

Authors:  Stephan Schwarz; Maximilian Müller; Tobias Ettl; Philipp Stockmann; Johannes Zenk; Abbas Agaimy
Journal:  Int J Clin Exp Pathol       Date:  2011-04-18

5.  Salivary gland cancers: biology and molecular targets for therapy.

Authors:  Diana Bell; Ehab Y Hanna
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

Review 6.  Ongoing challenges in the treatment of adenoid cystic carcinoma of the head and neck.

Authors:  T Subramaniam; P Lennon; J P O'Neill
Journal:  Ir J Med Sci       Date:  2015-04-17       Impact factor: 1.568

7.  Polymorphous low grade adenocarcinoma has a consistent p63+/p40- immunophenotype that helps distinguish it from adenoid cystic carcinoma and cellular pleomorphic adenoma.

Authors:  Lisa Rooper; Rajni Sharma; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2014-06-27

8.  Primary intraosseous adenoid cystic carcinoma of the mandible: histopathological and immunohistochemical analysis.

Authors:  Román Carlos-Bregni; Elisa C Vidaurre; Ana Carolina Netto; Jorge E León; Oslei P Almeida
Journal:  Pathol Oncol Res       Date:  2009-04-21       Impact factor: 3.201

9.  Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.

Authors:  S J Wong; T Karrison; D N Hayes; M S Kies; K J Cullen; T Tanvetyanon; A Argiris; N Takebe; D Lim; N F Saba; F P Worden; J Gilbert; H J Lenz; A R A Razak; J D Roberts; E E Vokes; E E W Cohen
Journal:  Ann Oncol       Date:  2015-11-23       Impact factor: 32.976

10.  Myoepithelial carcinoma of pharynx expressing KIT and PDGFRA.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.